Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10823198 | 0.98 | CA12 (0.59) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL10928119 | 0.91 | MGLL (0.53) | CA12CA1CA9CA2TSHR | |
| SCHEMBL1759227 | 0.91 | MGLL (0.53) | CA12CA1CA9CA2TSHR | |
| SCHEMBL751749 | 0.90 | CA12 (0.58) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL11210348 | 0.90 | CA12 (0.48) | CA12CA1CA9MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL11239450 | 0.89 | MGLL (0.52) | CA12CA1CA9CA2TSHR | |
| SCHEMBL8773488 | 0.87 | CA12 (0.56) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL673393 | 0.87 | CA12 (0.56) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL640838 | 0.87 | CA12 (0.56) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL154175 | 0.87 | CA12 (0.56) | CA12CA1CA9MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885239-B1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | BATRA SATISH (SE) | 2002-08-07 | — | — | EP | claimed |
| CN-113968823-A | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | 麻省理工学院 | 2022-01-25 | — | — | CN | disclosed |
| CN-107848988-B | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | 麻省理工学院 | 2021-10-22 | — | — | CN | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3132796-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2496617-B1 | URETHANES USED AS ADDITIVES IN A PHOTOPOLYMER FORMULATION | BAYER IP GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2497084-B1 | Selection method for additives in photopolymers | BAYER IP GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-0495091-B1 | AICA RIBOSIDE ANALOGS | METABASIS THERAPEUTICS INC (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0885239-A1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | Batra, Satish (SE) | 1998-12-23 | — | — | EP | disclosed |
| US-5777100-A | INCREASING LEVELS OF ADENOSINE, CARDIOVASCULAR, ISCHEMIA | GENSIA INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997027211-A1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | BATRA SATISH (SE) | 1997-07-31 | — | — | WO | disclosed |
| EP-0542867-A4 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | — | 1993-07-28 | — | — | EP | disclosed |
| EP-0542867-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA, INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0495091-A4 | AICA RIBOSIDE ANALOGS | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0495091-A1 | AICA RIBOSIDE ANALOGS | GENSIA, INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | CA12 273/4885CA1 205/4885CA9 445/4885 |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | CA12 273/4885CA1 205/4885CA9 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.